Eir Partners invests in PharmaForceIQ for growth in Miami

Eir Partners, a private equity firm specializing in healthcare technology, announced a majority recapitalization of PharmaForceIQ on September 10, 2024. This investment aims to enhance PharmaForceIQ's capabilities in product development, team expansion, and data asset accumulation, focusing on improving its omnichannel marketing solutions for healthcare professionals and patients. The partnership is expected to leverage PharmaForceIQ's unique AI-driven platform, which provides real-time omnichannel deployments and measurement for pharmaceutical and life science companies. Brett Carlson, Managing Partner of Eir Partners, expressed enthusiasm for the collaboration, emphasizing the potential to improve healthcare outcomes through timely information delivery. Neil Vangala, Managing Director at Eir, highlighted the commitment to work closely with PharmaForceIQ's founding team to refine product offerings and enhance customer experiences. This strategic partnership is anticipated to position PharmaForceIQ for significant growth in the competitive life sciences market. Eir Partners has a history of investing in life sciences, having previously executed a majority recapitalization into GiftHealth in 2023. The firm aims to expand its services and technology practice within various medical specialties, including gastroenterology and oncology. The addition of John Blakeley as Chairman of PharmaForceIQ further strengthens Eir's expertise in the sector. The financial advisory for PharmaForceIQ was provided by Canaccord Genuity LLC, while Eir Partners received legal counsel from McDermott Will and Emery, LLP. Financing for the transaction was facilitated by Twin Brook Capital Partners, indicating strong investor confidence in PharmaForceIQ's growth potential.